Deuruxolitinib for alopecia areata

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 5 Aug 2025: Trial started, NCT07133308
  2. 21 Aug 2025: Trial registered, NCT07133308

The trials

NCT07133308: Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

State
Under way
Phase
Phase 3
People
355 planned
Started
5 Aug 2025
Primary completion
May 2028
Arms
Treatment Period: Deuruxolitinib 8 mg, Open-Label Extension: Deuruxolitinib 8 mg BID
Results
None posted
  1. 5 Aug 2025: Trial started
  2. 21 Aug 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.